Specialised Therapeutics Signs an Exclusive License Agreement with Onconova Therapeutics for Rigosertib
Shots:
- Onconova to get clinical, regulatory and sales-based milestones up to $30.4M and royalties on sales. Specialised to receive exclusive rights to commercialize rigosertib in Australia and New Zealand
- The collaboration is focusing on the results of P-III INSPIRE study (NCT02562443) assessing Rigosertib IV + Best Supportive Care vs Physician’s Choice plus Best Supportive Care in ratio (2:1) with its 1EP as OS for patients with Myelodysplastic Syndromes (MDS)
- Rigosertib is a P-III candidate, enables blocking of cellular signaling by targeting RAS effector pathways and is evaluated in P-III as monothx & P-II in combination with azacitidine in 2L higher-risk MDS patients & 1L refractory higher-risk MDS patients respectively
Click here to read full press release/ article | Ref: PRNewswire | Image: Behance